Blood biomarkers in patients with bicuspid aortic valve disease. Issue 3 (September 2020)

• Record Type: Journal Article
• Authors: Bons, Lidia R.; Geenen, Laurie W.; van den Hoven, Allard T.; Dik, Willem A.; van den Bosch, Annemien E.; Duijnhouwer, Anthonie L.; Siebelink, Hans-Marc J.; Budde, Ricardo P.J.; Boersma, Eric; Wessels, Marja W.; van de Laar, Ingrid M.B.H.; DeRuiter, Marco C.; Goumans, Marie-José; Loeys, Bart L.; Roos-Hesselink, Jolien W.
• Is Part Of: Journal of cardiology. Volume 76:Issue 3(2020)
• Page Start: 287
• Page End: 294
• Publication Date: 2020-09
• Subjects: Transforming growth factor-beta 1 -- C-reactive protein -- Troponin T -- N-terminal pro-B-type natriuretic peptide -- Bicuspid aortic valve; Cardiology -- Periodicals; 616.12
• DOI: 10.1016/j.jjcc.2020.02.023
• Languages: English
• ISSNs: 0914-5087

Abstract

Highlights: A substantial number of patients with bicuspid aortic valve (BAV) have elevated levels of NT-proBNP, hsTnT, and hs-CRP. Higher NT-proBNP is associated with aortic valve stenosis and regurgitation in BAV patients. Higher hsTnT is associated with aortic valve regurgitation in BAV patients. BAV patients have lower transforming growth factor-beta 1 levels than healthy controls. This is the first study evaluating associations between biomarkers and disease stage in BAV patients. Abstract: Background: Patients with a bicuspid aortic valve (BAV) are at risk of developing valve deterioration and aortic dilatation. We aimed to investigate whether blood biomarkers are associated with disease stage in patients with BAV. Methods: Serum levels of high sensitivity C-reactive protein (hsCRP), high sensitivity troponin T (hsTnT), N-terminal pro-B-type natriuretic peptide (NT-proBNP), and total transforming growth factor-beta 1 (TGF-ß1) were measured in adult BAV patients with valve dysfunction or aortic pathology. Age-matched general population controls were included for TGFß-1 measurements. Correlation analyses and multivariable linear regression were used to determine the association between (2log-transformed) biomarker levels and aortic valve regurgitation, aortic valve stenosis, aortic dilatation, or left ventricular function. Results: hsCRP and hsTnT were measured in the total group of 183 patients (median age 34 years, 25th–75th percentile 23−46), NT-proBNP in 162 patients, and TGF-ß1 beta in 108 patients. Elevated levels of NT-proBNP were found in 20% of the BAV patients, elevated hsTnT in 6%, and elevated hsCRP in 7%. Higher hsTnT levels were independently associated with aortic regurgitation [odds ratio per doubling (OR2log ) 1.34, 95% CI 1.01;1.76] and higher NT-proBNP levels with aortic valve maximal velocity (ß2log 0.17, 95%CI 0.07;0.28) and aortic regurgitation (OR2log 1.41, 95%CI 1.11;1.79). Both BAV patients with (9.9 ± 2.7 ng/mL) and without aortic dilatation (10.4 ± 2.9 ng/mL) showed lower TGF-ß1 levels compared to general population controls (n = 85, 11.8 ± 3.2 ng/mL). Conclusions: Higher NT-proBNP and hsTNT levels were associated with aortic valve disease in BAV patients. TGF-ß1 levels were lower in BAV patients than in the general population, and not related to aortic dilatation. Longitudinal data are needed to further investigate the prognostic value of biomarkers in these patients.